Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30.
“At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.”
Abstracts accepted for presentation at AACR include:
Mini Symposium
INCB177054
INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity
(Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #3789.))
Poster Presentations
INCA33890
INCA33890 Increases CD8+ T-Cell Effector Function Compared with pembrolizumab as Assessed by Single-Cell RNA Sequencing in Human PD-1xTGFβR2 Knock-In Mouse Model (Session Title: Immune Fitness and Metabolic Regulation of Cancer Immunity. April 29, 10:00 a.m. – 1:00 p.m. ET (9:00 a.m. – 12:00 p.m. CT). Abstract #4861.))
INCA33890, a Bispecific Antibody Targeting PD-1 and TGFβR2, Shows Enhanced Immune Responses in Models of Ovarian Cancer
(Session Title: Antibodies 3: Multi-Target Checkpoint Inhibitors and Immune Activators. April 29, 3:00 p.m. – 6:00 p.m. ET (2:00 – 5:00 p.m. CT). Abstract #6074.))
PD-1xTGFβR2 Bispecific Biclonics® Antibody INCA33890 Augments Human T-Cell Effector Functions In Vitro and Ex Vivo
(Session Title: Antibodies 3: Multi-Target Checkpoint Inhibitors and Immune Activators. April 29, 3:00 p.m. – 6:00 p.m. ET (2:00 – 5:00 p.m. CT). Abstract #6071.))
INCB057643
INCB057643, a Bromodomain and Extra-Terminal (BET) Protein Inhibitor, Improved Bone Marrow Function and Shifted Megakaryopoiesis to Erythropoiesis in Patients with Myeloproliferative Neoplasms (MPNs)
(Session Title: Molecular Genetics and Epigenetics of Tumors. April 30, 10:00 a.m. – 1:00 p.m. ET (9:00 a.m. – 12:00 p.m. CT). Abstract #7188.))
Novel Role of INCB057643, a Bromodomain and Extra-Terminal (BET) Protein Inhibitor, in Myeloid Cell Regulation and Immunosuppressive Tumor Environment Remodeling in Myelofibrosis (MF)
(Session Title: Molecular Genetics and Epigenetics of Tumors. April 30, 10:00 a.m. – 1:00 p.m. ET (9:00 a.m. – 12:00 p.m. CT). Abstract #7184.))
Association of Cyclin E1 Expression with Genomic Instability in Ovarian Cancer
(Session Title: Origins and Mechanisms of Genomic Instability. April 28, 3:00 p.m. – 6:00 p.m. ET (2:00 – 5:00 p.m. CT). Abstract #2846.))
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
Incyte Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from Incyte’s clinical development pipeline, whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world, and Incyte’s goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners’ products; the acceptance of Incyte and its partners’ products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte’s reports filed with the Securities and Exchange Commission, including its annual report on form 10-K for the year ended December 31, 2024. Incyte disclaims any intent or obligation to update these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250425247226/en/
Contacts
Media
media@incyte.com
Investors
ir@incyte.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors22.5.2025 13:00:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share 23 abstracts featuring new data across its hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, May 30 – June 3, 2025. With two abstracts selected for rapid oral presentation, these data reflect the Company’s vision to address cancer across multiple fronts and provide innovative medicines to as many patients as possible worldwide. “ASCO is a powerful platform for highlighting progress in cancer care, and we’re proud to contribute 23 accepted abstracts that reflect our mission to improve outcomes for more patients around the world,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “From long-term follow-up results for BRUKINSA in CLL to first-time clinical data for two promising breast cancer assets, our presentations this year spea
Quant Makes Money Smarter With Rollout of Industry-Wide Programmable Money22.5.2025 11:07:00 EEST | Press release
Quant, a global leader in fintech and innovation, today announces the rollout of Quant Flow, an industry-first programmable money and banking infrastructure now available via a white-label solution to banks, institutions and corporates across Europe, the Middle East, and APAC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522277808/en/ Gilbert Verdain, CEO of Quant Quant Flow was developed in response to the growing demand for smarter forms of commercial bank money and the need to modernise financial infrastructure, driven by rising regulatory pressure and competition from stablecoins, central bank digital currencies (CBDCs), neobanks and fintechs. Quant Flow delivers automation and intelligence directly into money at the account level. For banks, this means they can respond to market demand, address regulation, innovate with new forms of money and defend profitability – all without the need for costly system overhauls.
Manchester City Puts Smart Water Tech in Play on the Pitch22.5.2025 11:00:00 EEST | Press release
Manchester City Football Club is using data and analytics for more than performance on the pitch. A champion of water sustainability, the Club is taking its commitment to the next level – introducing digital solutions from its official water technology partner, Xylem (NYSE: XYL), to help capture and reuse rainwater more efficiently. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522922860/en/ Manchester City Football Club is teaming up with Xylem to bring smart water management to City Football Academy. With the help of Xylem Vue, the Club is capturing and reusing rainwater more efficiently through data and analytics. At City Football Academy, Xylem Vue – a digital water platform – uses connected sensors and smart meters to deliver live insights into how water moves across the training facility. Showing exactly when and where water is being used or lost across the 16.5-pitch campus, the system helps the Club make smarter
Pure Lithium and E3 Lithium Report Results From Phase 1 of the Lithium Metal Battery Joint Development Agreement22.5.2025 10:15:00 EEST | Press release
Pure Lithium Corporation, a disruptive vertically integrated lithium metal battery technology company, is pleased to announce initial results from the battery cells manufactured under the Joint Development Agreement with E3 Lithium, using E3 Lithium’s brines and DLE technology and Pure Lithium’s innovative extraction and battery technology. Several variations of E3’s lithium chloride concentrate were used to make lithium metal anodes at Pure Lithium’s Boston facility. The lithium from the E3 concentrated lithium chloride was electrodeposited as pure lithium metal onto a copper substrate, creating a complete, battery ready anode. These anodes were then assembled by Pure Lithium into batteries, and their electrochemical performance was evaluated in full cells. Notable results include: Lithium Metal Purity: The various E3 brine streams all achieved a very high purity level, > 99.9% pure lithium metal as tested by ICP-OES analysis. Cell Performance (Life Cycle): This tests for the number o
Manhattan Associates Unveils Agentic AI Innovation at Momentum 202522.5.2025 10:00:00 EEST | Press release
Kicking off Momentum 2025, Manhattan Associates Inc. (NASDAQ: MANH) today announced sweeping Agentic AI support within Manhattan Active® solutions that includes intelligent, autonomous digital agents to revolutionise supply chain commerce execution, optimisation, and user experiences. These out-of-the-box AI agents, powered by large language models (LLMs) and Manhattan’s cloud-native, all-microservice API architecture, will autonomously perform tasks, adapt to changing conditions, and dynamically orchestrate workflows. This breakthrough marks a generational leap from traditional chatbots and static workflow configurations to dynamic, intelligent, and situationally aware orchestration across the entire supply chain and commerce lifecycle. Among the first groundbreaking AI agents announced are the Intelligent Store Manager, Labor Optimizer Agent, Wave Inventory Research Agent, Contextual Data Assistant, and Virtual Configuration Consultant. These digital agents allow users to interact wi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom